IBM Watson Health and the Broad Institute of MIT and Harvard have launched a five-year $50 million research project to delve into cancer drug resistance.
Researchers will study thousands of drug-resistant tumors and draw on Watson’s computational and machine learning methods to understand how cancers become resistant to therapies.
Drug resistance is a major cause of nearly 600,000 annual cancer deaths in the United States alone. In a limited number of cases, scientists have discovered the cause of drug resistance, allowing the development of new drugs to overcome it.
